CAR-T cell therapy’s promise and pitfalls: Systemic barriers to equitable cancer treatment access in global health systems
Original framing: “Treating previously untreatable cancers: How CAR-T cell therapy could be made accessible to more patients” — The Conversation - Global
Marginalized voices—including Black, Indigenous, disabled, and low-income patients—are systematically excluded from CAR-T discourse despite bearing disproportionate cancer burdens. In the U.S., Black patients are 20% less likely to access CAR-T than white patients due to referral biases and insurance barriers. Global South patients, who represent 70% of cancer deaths, are treated as 'markets' for Western therapies rather than co-creators of solutions. Disabled communities, who face higher cancer risks due to environmental toxins and healthcare discrimination, are absent from clinical trial designs. Their exclusion ensures that 'accessibility' remains a euphemism for 'affordability for the global elite.'
The CAR-T therapy narrative exemplifies how medical innovation is co-opted by neoliberal structures, where breakthroughs like CAR-T are framed as apolitical miracles while their structural exclusions—patent regimes, racialized healthcare access, and colonial-era IP laws—are rendered invisible.
Historically, this mirrors the apartheid-era medical apartheid and Tuskegee experiments, where marginalized bodies were treated as experimental material for 'progress' that never reached them. Cross-culturally, indigenous and traditional systems (e.g., Ayurveda, Ubuntu) offer holistic alternatives that could democratize care if integrated into systemic solutions. Scientifically, the focus on academic cost-cutting obscures how Big Pharma’s monopolies and supply chain fragilities (exacerbated by climate change) perpetuate inequity. Future models must center epistemic justice, decolonized IP, and climate resilience—such as open-source hubs in Rwanda or India’s *CAR-T 2.0*—to ensure that CAR-T’s promise isn’t confined to the global elite. Without these shifts, the therapy will remain a symbol of health apartheid, where 'untreatable' cancers are redefined as 'unaffordable' for most of the world.